Keyphrases
Antibiotic Prophylaxis
12%
AXL Inhibition
22%
Cancer Patients
15%
Cancer Types
14%
Chemotherapy Resistance
13%
Chemotherapy Response
13%
Complication Rate
22%
Confidence Interval
12%
COVID-19 Pandemic Impact
22%
Endometrial Cancer
43%
Excision
22%
Gynecologic Malignancies
17%
Gynecologic Oncology
66%
Gynecologic Surgery
14%
Gynecological Cancer
30%
High-grade Serous Ovarian Cancer (HGSOC)
32%
Homologous Recombination Deficiency
13%
Hysterectomy
15%
Immunohistochemistry
16%
Oncology Care
14%
Oncology Patients
25%
Organoids
19%
Ovarian Cancer
43%
Ovarian Cancer Patients
46%
Ovarian Metastasis
13%
Ovarian Organoid
14%
Overall Survival
28%
Paclitaxel
13%
Palliative Care
22%
PARP Inhibitor (PARPi)
13%
Patient-derived
19%
Patient-derived Organoids
22%
Perioperative Antibiotics
12%
Platinum-based Chemotherapy
18%
Predictive Biomarker
15%
Primary Tumor
14%
Prophylactic Antibiotics
12%
RAD51 Foci
16%
Recurrent Endometrial Cancer
13%
Sensitivity to Chemotherapy
12%
Society of Gynecologic Oncology
14%
Survival Outcomes
17%
Treatment Options
16%
Tumor
26%
Tumor Burden
14%
Tumor Cells
28%
Tumor Microenvironment
23%
Vertical Incision
14%
Vulvar
14%
Wound Complications
40%
Medicine and Dentistry
Acute Chest Syndrome
11%
Adipose Tissue
11%
Antibiotics
14%
Biological Marker
15%
Cancer
20%
Cell Line
19%
Chlamydia Trachomatis
11%
COVID-19
22%
Cytoreductive Surgery
11%
Direct Oral Anticoagulant
11%
Diseases
18%
DNA Damage
11%
DNA Repair
14%
Drug Screening
11%
End of Life Care
11%
Female Genital Tract Cancer
25%
Frailty
13%
Frailty Index
22%
Gestagen
11%
Gynecological Oncology
66%
Gynecological Surgery
14%
Homologous Recombination
17%
Hysterectomy
15%
Immunofluorescence Test
11%
Immunohistochemistry
14%
Immunotherapy
11%
In Vitro
11%
Incision
13%
Malignant Neoplasm
25%
Mesothelial Cell
12%
Metastatic Carcinoma
25%
Neoplasm
50%
Organoid
44%
Ovarian Cancer
100%
Overall Survival
21%
Paclitaxel
12%
Patient Referral
16%
Poly ADP Ribose Polymerase
13%
Primary Health Care
11%
Primary Tumor
11%
Randomized Controlled Trial
12%
Recurrent Disease
13%
Sickle Cell
11%
Subcutaneous Fat
11%
Symptomatic Treatment
22%
Tumor Cell
25%
Uterine Cancer
40%
Visceral Fat
11%
Vulvar Cancer
11%
Wound Complication
39%